1003-60-7

Basic information

• Product Name: 2-Methylthiazole-5-carbaldehyde
• Synonyms: 2-Methylthiazole-5-carbaldehyde;2-methyl-1,3-thiazole-5-carbaldehyde(SALTDATA: FREE);5-Formyl-2-methyl-1,3-thiazole;2-Methylthiazol-5-carbaldehyde;2-Methylthiazole-5-carboxaldehyde;5-Thiazolecarboxaldehyde, 2-Methyl-;2-Methylthiazole-5-carbaldehyde≥ 99% (Assay)
• CAS NO: 1003-60-7
• Molecular Formula: C₅H₅NOS
• Molecular Weight: 127.17
• Product Categories: Building Blocks;Thiazole
• Mol File: 1003-60-7.mol

Chemical Properties

• Boiling Point: 218.993 °C at 760 mmHg
• Flash Point: 86.244 °C
• Appearance: /
• Density: 1.271 g/cm³
• Vapor Pressure: 0.122mmHg at 25°C
• Refractive Index: 1.601
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: 1.66±0.10(Predicted)
• CAS DataBase Reference: 2-Methylthiazole-5-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Methylthiazole-5-carbaldehyde(1003-60-7)
• EPA Substance Registry System: 2-Methylthiazole-5-carbaldehyde(1003-60-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 1003-60-7(Hazardous Substances Data)

Usage

Chemical Properties

Yellowish orange solid

InChI:InChI=1/C5H5NOS/c1-4-6-2-5(3-7)8-4/h2-3H,1H3

Upstream product

• 2065-75-0 2-Bromo-malonaldehyde 
• 62-55-5 thioacetamide 
• 79836-78-5 ethyl 2-methylthiazole-5-carboxylate 
• 56012-38-5 5-(hydroxymethyl)-2-methylthiazole 
• 36437-19-1 2-chloromalonaldehyde 

Downstream Products

• 56012-38-5 5-(hydroxymethyl)-2-methylthiazole 
• 63139-99-1 N,2-dimethyl-5-thiazole-methane-amine 

Relevant articles and documents

Convergent, parallel synthesis of a series of β-substituted 1,2,4-oxadiazole butanoic acids as potent and selective α vβ3 receptor antagonists

We describe a series of 1,2,4-oxadiazoles, which are potent antagonists of the integrin αvβ3 and, in addition, show selectivity relative to the other β3 integrin αIIbβ3. In whole cells, the majority o

SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS

The present invention refers to novel substituted thiazole and oxazole compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties. The compounds are useful in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans.

TRICYCLIC IMIDAZOLE COMPOUNDS AS INHIBITORS OF TRYPTOPHAN HYDROXYLASE

The present invention relates to compounds of the formula (I), wherein R1a, R1b, R2, R3, and X are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to thei

TRICYCLIC PIPERIDINE COMPOUNDS

The present invention relates to compounds of the formula (I), wherein R, R1a, R1b, R2, R3, and X are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), to methods for the preparation of such compounds of formula (I), and especially to their use as TPH modulators.

BENZAZEPINE DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF

Compounds of the general formula (I): or salts thereof, which exhibit CCR5 antagonism and exert preventive and therapeutic effects against HIV infections: wherein R1 is a 5- to 6-membered aromatic ring which bears a substituent represented by the general formula: R-Z1-X-Z2- (wherein R1 is hydrogen or optionally substituted hydrocarbyl; X is optionally substituted alkylene; and Z1 and Z2 are each a heteroatom) and may be further substituted, with R being optionally bonded to the aromatic ring to form another ring; Y is optionally substituted imino; and R2 and R3 are each optionally substituted aliphatic hydrocarbyl or an optionally substituted hetero-alicyclic group.

Selective cyclooxygenase-2 inhibitors: Heteroaryl modified 1,2-diarylimidazoles are potent, orally active antiinflammatory agents

A series of heteroaryl modified 1,2-diarylimidazoles has been synthesized and found to be potent and highly selective (1000-9000-fold) inhibitors of the human COX-2.3-Pyridyl derived COX-2 selective inhibitor (25) exhibited excellent activity in acute (carrageenan induced paw edema, ED50 = 5.4 mg/kg) and chronic (adjuvant induced arthritis, ED50 = 0.25 mg/kg) models of inflammation. The relatively long half-life of 25 in rat and dog prompted investigation of the pyridyl and other heteroaromatic systems containing potential metabolic functionalities. A number of substituted pyridyl and thiazole containing compounds (e.g., 44, 46, 54, 76, and 78) demonstrated excellent oral activity in every efficacy model evaluated. Several orally active diarylimidazoles exhibited desirable pharmacokinetics profiles and showed no GI toxicity in the rat up to 100 mg/kg in both acute and chronic models. The paper describes facile and practical syntheses of the targeted diarylimidazoles. The structure-activity relationships and antiinflammatory properties of a series of diarylimidazoles are discussed.